Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
 
 

Publication of Q3 2016 Results

“We had a good third quarter and are lifting our guidance for the full year. We have made good progress with the execution of our strategy. We have advanced our pharmaceutical pipeline and are realizing the cost synergies from the acquisition of Sigma-Aldrich faster than planned. In the course of the year, we have lowered our debt from the acquisition by € 1 billion.” Stefan Oschmann, CEO and Chairman of the Executive Board

Investing in China

By 2018, China will be the world’s second-largest pharmaceutical market. That’s why we are boosting our investments in China. In Nantong, we have inaugurated a new pharmaceutical manufacturing site to produce medicines on China’s Essential Drugs List for the treatment of diabetes, cardiovascular disease and thyroid disorders.

We will achieve our objectives

By prioritizing and advancing the pharma pipeline, successfully integrating the Life Science business, and capturing new markets for our Performance Materials business we are well on our way to achieving our objectives for 2018.  This will allow us to remain a leader at the forefront of scientific and technological progress. We are informing analysts and investors about these developments today at our Capital Market Day in Darmstadt.

The car of the future

Autonomous driving, alternative engine types, online communication, adaptive headlights, multiple design options for interior lighting, free-form displays – the car of tomorrow will set new standards in terms of functionality and aesthetics. With our futuristic concept car, we are venturing a look into the future and are pointing out the areas where our materials can be used.

 

Media Services for the US and Canada

MilliporeSigma Expands Distribution Agreement with Roche
MilliporeSigma Expands Distribution Agreement with Roche
MilliporeSigma today announced an expansion of its distribution alliance with Roche to include the polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products of Kapa Biosystems, a company acquired by Roche in 2015.
 
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
Darmstadt, Germany, and New York, US, November 29, 2016 – Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for avelumab, which was submitted by EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada.
 
Business results for Q3 2016
Strong third quarter
Darmstadt, Germany, November 15, 2016 – “We had a good third quarter and are lifting our guidance for the full year. We have made good progress with the execution of our strategy. We have advanced our pharmaceutical pipeline and are realizing the cost synergies from the acquisition of Sigma-Aldrich faster than planned. In the course of the year, we have lowered our debt from the acquisition by € 1 billion.” Stefan Oschmann, CEO and Chairman of the Executive Board.
 
 
top

OUR COMPANY IN THE MEDIA

OUR COMPANY IN THE MEDIA
Read how Merck KGaA, Darmstadt, Germany, and its affiliates are covered by media outlets around the world

DOWNLOAD LIBRARY

Download Library
Download images, Media Kits and other material from our media download library

CALENDAR OF EVENTS

Calendar of Events
Find and register for upcoming events

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
 

FOR MEDIA INQUIRIES, CONTACT

Media Team
POSTAL ADDRESS 
Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250 
64293 Darmstadt 
Germany
Tel.: +49 6151 72-5000
Fax: +49 6151 72-3138
 

GENERAL INQUIRIES

Communications Center
Tel.: +49 6151 72-0
Fax: +49 6151 72-2000
 

CURRENT FINANCIAL REPORT

Current Financial Report
Merck KGaA, Darmstadt, Germany on Facebook
Twitter